CEMI:NSD-Chembio Diagnostics, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 5.34

Change

0.00 (0.00)%

Market Cap

USD 0.11B

Volume

1.38M

Average Target Price

USD 7.33 (+37.33%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

USD44.38B 69.79 40.40
IDXX IDEXX Laboratories, Inc

N/A

USD38.08B 80.89 56.16
DXCM DexCom, Inc

N/A

USD30.01B 129.45 78.92
EXAS Exact Sciences Corporation

N/A

USD17.43B N/A N/A
GH Guardant Health, Inc

N/A

USD11.26B N/A N/A
ICLR ICON Public Limited Company

N/A

USD9.93B 31.56 21.32
QDEL Quidel Corporation

N/A

USD7.60B 21.94 15.23
NTRA Natera, Inc

N/A

USD7.22B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD7.06B 32.92 18.88
OZON Ozon Holdings PLC

N/A

USD6.91B N/A N/A

ETFs Containing CEMI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.11% 50% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.11% 50% F 66% D
Trailing 12 Months  
Capital Gain 26.24% 50% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.24% 50% F 68% D+
Trailing 5 Years  
Capital Gain 1.14% 48% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.14% 48% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 3.86% N/A N/A 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.86% N/A N/A 45% F
Risk Return Profile  
Volatility (Standard Deviation) 38.46% N/A N/A 34% F
Risk Adjusted Return 10.03% N/A N/A 39% F
Market Capitalization 0.11B 33% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.01 80% B- 42% F
Price / Cash Flow Ratio -11.90 71% C- 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -74.57% 33% F 16% F
Return on Invested Capital -33.95% 46% F 24% F
Return on Assets -18.13% 43% F 20% F
Debt to Equity Ratio 73.41% 29% F 32% F
Technical Ratios  
Short Ratio 3.29 48% F 50% F
Short Percent 20.89% 9% F 10% F
Beta 2.12 13% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector